PAX3 and rhabdomyosarcoma: All Fusion+ rhabdomyosarcoma (RMS) models harbored a hallmark PAX3-FOXO1 fusion (Figure 2C; Table S1), and the median patient age of Fusion+ RMS patients (16 years) was higher than that of Fusion− RMS patients (5 years) (Table S3).